Company intelligence / Profile preview

Zeria Pharmaceutical

Tokyo, Japan

Ownership: Private
Employees: ~1839
Development stage: Other

Overview

Zeria Pharmaceutical specializes in gastrointestinal diseases, with several products approved and marketed in Japan and globally, notably leading in gastroenterology and holding global rights to mesalazine (Asacol). The company’s flagship original drug Acofide (acotiamide) is first-in-class for functional dyspepsia. Through its subsidiary Tillotts Pharma, it continues innovation in lower GI therapeutics and new formulations. Its pipeline includes new drugs for GI and cancer cachexia and ongoing clinical expansion.

Therapeutic areas: ImmunologyGastroenterologyNephrologyOncologyCardiovascularEndocrinology
Modalities: Small moleculeAntibodyPolymerBiological productsChemical drugs
Industry: Biotech

Partnerships

Agastra-Lab s.r.l (development and marketing of acotiamide hydrochloride hydrate)Former Kyowa Kirin (ASACOL commercial rights, now fully held by Zeria)

Beyond the preview

Go deeper on Zeria Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zeria Pharmaceutical.

Explore the full profile